Dopamine agonists modify the course of Parkinson disease

Archives of Neurology

Volumn 61, Issue 12, 2004, Pages 1969-1971

  Stern, Matthew B ^a  

^a Penn Neurological Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE;

DOPAMINE AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 10044237961     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.12.1969     Document Type: Article

References (23)

1. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology. 1996;47(suppl 3):S146-S152.
2. Fahn S; the Parkinson Study Group. Results of the ELLDOPA study (earlier vs later levodopa) study. Mov Disord. 2003;17(suppl 5):S13-S14.
3. Chase T, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. 1989;39:7-10.
4. Olanow W, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 2000; 23(suppl 10):S117-S126.
5. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a four-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
6. Rascol O, Brooks D, Korczyn A, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000; 342:1484-1491
7. Parkinson Study Group. Pramipexole vs levodopa as initial treatment lor Parkinson's disease: a randomized controlled clinical trial. JAMA. 2000;284:1931-1938.
8. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry. 1994;57:1034-1038.
9. Oertel WH. Pergolide versus levodopa (PELMOPET). Mov Disord. 2000;15(suppl 3):4.
10. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs. 1998;55:23-30.
11. Corrigan MH, Denihan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety. 2000;11:58-65.
12. Bennett JP, Carvey PM, Hinds TR, et al. Mechanisms of action of pramipexole: putative neuroprotective effects. Rev Contemp Pharmacother. 2001;12:33-57.
13. Felton DL, Felton SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging. 1992;13:339-351.
14. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999;838:51-59.
15. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 1994;657:207-213.
16. Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol. 2002; 9(suppl3):7-14.
17. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression, JAMA. 2002;287:1653-1661.
18. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101.
19. Ahlskog JE, Uitti RJ, O'Conner MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord. 1999;14:940-946.
20. 123|β-CIT. Mov Disord. 1999;14:436-442.
21. Albin RL, Frey KA. Initial agonist treatment of Parkinson's disease: a critique. Neurology. 2003; 60:390-394.
22. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60;381-389.
23. Woolen GF. Agonists vs levodopa in PD. Neurology. 2003;60:360-362.